{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:39:52Z","timestamp":1791549592774,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370225"],"award-info":[{"award-number":["82370225"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-01600-3","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:56:43Z","timestamp":1747454203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status"],"prefix":"10.1038","volume":"15","author":[{"given":"Xunyi","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianshan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"issue":"8","key":"1600_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol, F. & Ganser, A. Treatment of relapsed acute myeloid leukemia. Curr. Treat. Options Oncol. 21 (8), 66. https:\/\/doi.org\/10.1007\/s11864-020-00765-5 (2020).","journal-title":"Curr. Treat. Options Oncol."},{"issue":"8","key":"1600_CR2","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.25162","volume":"93","author":"C Ganzel","year":"2018","unstructured":"Ganzel, C. et al. Very poor long-term survival in past and more recent studies for relapsed aml patients: the ecog-acrin experience. Am. J. Hematol. 93 (8), 1074\u20131081. https:\/\/doi.org\/10.1002\/ajh.25162 (2018).","journal-title":"Am. J. Hematol."},{"issue":"12","key":"1600_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner, H. et al. Diagnosis and management of aml in adults: 2022 recommendations from an international expert panel on behalf of the Eln. Blood 140 (12), 1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867 (2022).","journal-title":"Blood"},{"issue":"1","key":"1600_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","volume":"31","author":"J Prada-Arismendy","year":"2017","unstructured":"Prada-Arismendy, J., Arroyave, J. C. & Rothlisberger, S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 31 (1), 63\u201376. https:\/\/doi.org\/10.1016\/j.blre.2016.08.005 (2017).","journal-title":"Blood Rev."},{"issue":"7","key":"1600_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nbt0713-577","volume":"31","author":"A Bouchie","year":"2013","unstructured":"Bouchie, A. First Microrna mimic enters clinic. Nat. Biotechnol. 31 (7), 577. https:\/\/doi.org\/10.1038\/nbt0713-577 (2013).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"1600_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12943-016-0518-2","volume":"15","author":"CH Yeh","year":"2016","unstructured":"Yeh, C. H., Moles, R. & Nicot, C. Clinical significance of Micrornas in chronic and acute human leukemia. Mol. Cancer. 15 (1), 37. https:\/\/doi.org\/10.1186\/s12943-016-0518-2 (2016).","journal-title":"Mol. Cancer"},{"key":"1600_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1479-5876-11-31","volume":"11","author":"H Fayyad-Kazan","year":"2013","unstructured":"Fayyad-Kazan, H. et al. Circulating mir-150 and mir-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J. Transl Med. 11, 31. https:\/\/doi.org\/10.1186\/1479-5876-11-31 (2013).","journal-title":"J. Transl Med."},{"issue":"6","key":"1600_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1586\/17474086.2014.959921","volume":"7","author":"R Wouters","year":"2014","unstructured":"Wouters, R., Cucchi, D., Kaspers, G. J., Schuurhuis, G. J. & Cloos, J. Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design. Expert Rev. Hematol. 7 (6), 791\u2013805. https:\/\/doi.org\/10.1586\/17474086.2014.959921 (2014).","journal-title":"Expert Rev. Hematol."},{"issue":"11","key":"1600_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/s41423-018-0047-6","volume":"15","author":"IM Yasinska","year":"2018","unstructured":"Yasinska, I. M. et al. Biochemical mechanisms implemented by human acute myeloid leukemia cells to suppress host immune surveillance. Cell. Mol. Immunol. 15 (11), 989\u2013991. https:\/\/doi.org\/10.1038\/s41423-018-0047-6 (2018).","journal-title":"Cell. Mol. Immunol."},{"issue":"8","key":"1600_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00262-024-03738-x","volume":"73","author":"A Liu","year":"2024","unstructured":"Liu, A. et al. Two nomograms constructed for predicting the efficacy and prognosis of advanced non\u2013small cell lung cancer patients treated with anti\u2013pd\u20131 inhibitors based on the absolute counts of lymphocyte subsets. Cancer Immunol. Immunother. 73 (8), 152. https:\/\/doi.org\/10.1007\/s00262-024-03738-x (2024).","journal-title":"Cancer Immunol. Immunother"},{"key":"1600_CR11","doi-asserted-by":"publisher","first-page":"107824","DOI":"10.1016\/j.lungcan.2024.107824","volume":"192","author":"M Szentkereszty","year":"2024","unstructured":"Szentkereszty, M., Ladanyi, A., Galffy, G., Tovari, J. & Losonczy, G. Density of tumor-infiltrating Nk and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma. Lung Cancer. 192, 107824. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107824 (2024).","journal-title":"Lung Cancer"},{"key":"1600_CR12","doi-asserted-by":"publisher","first-page":"1364507","DOI":"10.3389\/fimmu.2024.1364507","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang, X., Li, Q. & Zeng, T. Peripheral cd4(+) t cells correlate with response and survival in patients with advanced non-small cell lung cancer receiving chemo-immunotherapy. Front. Immunol. 15, 1364507. https:\/\/doi.org\/10.3389\/fimmu.2024.1364507 (2024).","journal-title":"Front. Immunol."},{"issue":"1","key":"1600_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12967-024-05142-6","volume":"22","author":"A Gelibter","year":"2024","unstructured":"Gelibter, A. et al. Cd137(+) and regulatory t cells as independent prognostic factors of survival in advanced non-oncogene addicted Nsclc patients treated with immunotherapy as first-line. J. Transl Med. 22 (1), 329. https:\/\/doi.org\/10.1186\/s12967-024-05142-6 (2024).","journal-title":"J. Transl Med."},{"issue":"1","key":"1600_CR14","doi-asserted-by":"publisher","first-page":"12799","DOI":"10.1038\/s41598-024-61632-z","volume":"14","author":"H Zhang","year":"2024","unstructured":"Zhang, H., Li, Y., Liu, Y. W., Liu, Y. G. & Chen, X. Predictive value of lymphocyte subsets and lymphocyte-to-monocyte ratio in assessing the efficacy of neoadjuvant therapy in breast cancer. Sci. Rep. 14 (1), 12799. https:\/\/doi.org\/10.1038\/s41598-024-61632-z (2024).","journal-title":"Sci. Rep."},{"issue":"1","key":"1600_CR15","doi-asserted-by":"publisher","first-page":"11576","DOI":"10.1038\/s41598-024-60243-y","volume":"14","author":"IV Goncalves","year":"2024","unstructured":"Goncalves, I. V. et al. Dynamic changes in B cell subpopulations in response to triple-negative breast cancer development. Sci. Rep. 14 (1), 11576. https:\/\/doi.org\/10.1038\/s41598-024-60243-y (2024).","journal-title":"Sci. Rep."},{"issue":"8","key":"1600_CR16","doi-asserted-by":"publisher","first-page":"e18248","DOI":"10.1111\/jcmm.18248","volume":"28","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Prognostic and immunotherapeutic potential of regulatory t cell-associated signature in ovarian cancer. J. Cell. Mol. Med. 28 (8), e18248. https:\/\/doi.org\/10.1111\/jcmm.18248 (2024).","journal-title":"J. Cell. Mol. Med."},{"key":"1600_CR17","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673296618240424095548","author":"H Shi","year":"2024","unstructured":"Shi, H., Li, Z. & Zhu, M. Circulating immune cells predict prognosis and clinical response to chemotherapy in cholangiocarcinoma. Curr. Med. Chem. https:\/\/doi.org\/10.2174\/0109298673296618240424095548 (2024).","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"1600_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s10238-022-00867-4","volume":"23","author":"Z Yang","year":"2023","unstructured":"Yang, Z. & Yu, W. Clinical significance of Circulating neutrophils and lymphocyte subsets in newly diagnosed patients with diffuse large b-cell lymphoma. Clin. Exp. Med. 23 (3), 815\u2013822. https:\/\/doi.org\/10.1007\/s10238-022-00867-4 (2023).","journal-title":"Clin. Exp. Med."},{"issue":"4","key":"1600_CR19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00277-023-05583-x","volume":"103","author":"AC Olivas-Bejarano","year":"2024","unstructured":"Olivas-Bejarano, A. C. et al. Lymphocyte subsets and soluble forms of mic-a and mic-b are prognostic factors in non-hodgkin lymphoma patients. Ann. Hematol. 103 (4), 1317\u20131325. https:\/\/doi.org\/10.1007\/s00277-023-05583-x (2024).","journal-title":"Ann. Hematol."},{"issue":"6","key":"1600_CR20","doi-asserted-by":"publisher","first-page":"6956","DOI":"10.1002\/cam4.5492","volume":"12","author":"P Vodarek","year":"2023","unstructured":"Vodarek, P. et al. A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia. Cancer Med. 12 (6), 6956\u20136970. https:\/\/doi.org\/10.1002\/cam4.5492 (2023).","journal-title":"Cancer Med."},{"issue":"1","key":"1600_CR21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1186\/s12885-019-5971-z","volume":"19","author":"M Gauthier","year":"2019","unstructured":"Gauthier, M. et al. Prognostic role of cd4 t-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia. Bmc Cancer. 19 (1), 809. https:\/\/doi.org\/10.1186\/s12885-019-5971-z (2019).","journal-title":"Bmc Cancer"},{"issue":"11","key":"1600_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood.V112.11.3175.3175","volume":"112","author":"A Egle","year":"2008","unstructured":"Egle, A. et al. Minimal residual disease (mrd) and t \/ Nk cell dynamics during fludarabine, cyclophosphamide plus rituximab (fcr) followed by fludarabine plus rituximab (fr) and remission maintenance therapy with rituximab in previously untreated b-chronic lymphocytic leukemia (b-cll): riskfactor stratification in the Chairos study. Blood 112 (11), 1089 (2008).","journal-title":"Blood"},{"issue":"6","key":"1600_CR23","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","volume":"106","author":"M Beyer","year":"2005","unstructured":"Beyer, M. et al. Reduced frequencies and suppressive function of cd4\u2009+\u2009cd25hi regulatory t cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106 (6), 2018\u20132025. https:\/\/doi.org\/10.1182\/blood-2005-02-0642 (2005).","journal-title":"Blood"},{"issue":"2","key":"1600_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/ijlh.12594","volume":"39","author":"M Alcasid","year":"2017","unstructured":"Alcasid, M., Ma, L., Gotlib, J. R., Arber, D. A. & Ohgami, R. S. The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia. Int. J. Lab. Hematol. 39 (2), 129\u2013136. https:\/\/doi.org\/10.1111\/ijlh.12594 (2017).","journal-title":"Int. J. Lab. Hematol."},{"issue":"7","key":"1600_CR25","doi-asserted-by":"publisher","first-page":"7586","DOI":"10.18632\/oncotarget.7210","volume":"7","author":"FE Sander","year":"2016","unstructured":"Sander, F. E. et al. Dynamics of cytotoxic t cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. Oncotarget 7 (7), 7586\u20137596. https:\/\/doi.org\/10.18632\/oncotarget.7210 (2016).","journal-title":"Oncotarget"},{"issue":"4","key":"1600_CR26","first-page":"517","volume":"20","author":"DB Milosevic","year":"2001","unstructured":"Milosevic, D. B. The different level of immunological recovery after chemotherapy in leukemia and lymphoma patients. J. Exp. Clin. Cancer Res. 20 (4), 517\u2013522 (2001).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"1600_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/pbc.21327","volume":"50","author":"S Kosmidis","year":"2008","unstructured":"Kosmidis, S. et al. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with all. Pediatr. Blood Cancer. 50 (3), 528\u2013532. https:\/\/doi.org\/10.1002\/pbc.21327 (2008).","journal-title":"Pediatr. Blood Cancer"},{"key":"1600_CR28","doi-asserted-by":"publisher","unstructured":"[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not apl). ]. Zhonghua Xue Ye Xue Za Zhi 2023;44(9):705\u2009\u2013\u200912. (2023). https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.09.001","DOI":"10.3760\/cma.j.issn.0253-2727.2023.09.001"},{"key":"1600_CR29","doi-asserted-by":"publisher","unstructured":"[Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia. ]. Zhonghua Xue Ye Xue Za Zhi 2018;39(3):179\u2009\u2013\u200983. (2018). https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2018.03.002","DOI":"10.3760\/cma.j.issn.0253-2727.2018.03.002"},{"key":"1600_CR30","doi-asserted-by":"publisher","unstructured":"Ferraro, F. et al. Immunosuppression and outcomes in adult patients with de Novo acute myeloid leukemia with normal karyotypes. Proc. Natl. Acad. Sci. U S A. 118 (49). https:\/\/doi.org\/10.1073\/pnas.2116427118 (2021).","DOI":"10.1073\/pnas.2116427118"},{"issue":"4","key":"1600_CR31","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/imm.12665","volume":"149","author":"D Ozkazanc","year":"2016","unstructured":"Ozkazanc, D., Yoyen-Ermis, D., Tavukcuoglu, E., Buyukasik, Y. & Esendagli, G. Functional exhaustion of cd4(+) t cells induced by co-stimulatory signals from myeloid leukaemia cells. Immunology 149 (4), 460\u2013471. https:\/\/doi.org\/10.1111\/imm.12665 (2016).","journal-title":"Immunology"},{"issue":"8","key":"1600_CR32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into t cell exhaustion. Nat. Rev. Immunol. 15 (8), 486\u2013499. https:\/\/doi.org\/10.1038\/nri3862 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1600_CR33","doi-asserted-by":"publisher","unstructured":"Sato, Y. et al. Cd4\u2009+\u2009t cells induce rejection of urothelial tumors after immune checkpoint Blockade. Jci Insight. 3 (23). https:\/\/doi.org\/10.1172\/jci.insight.121062 (2018).","DOI":"10.1172\/jci.insight.121062"},{"issue":"10","key":"1600_CR34","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1002\/ijc.29563","volume":"137","author":"Q Tao","year":"2015","unstructured":"Tao, Q. et al. Regulatory t cells-derived il-35 promotes the growth of adult acute myeloid leukemia blasts. Int. J. Cancer. 137 (10), 2384\u20132393. https:\/\/doi.org\/10.1002\/ijc.29563 (2015).","journal-title":"Int. J. Cancer"},{"issue":"10","key":"1600_CR35","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1182\/blood.v99.10.3661","volume":"99","author":"RT Costello","year":"2002","unstructured":"Costello, R. T. et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99 (10), 3661\u20133667. https:\/\/doi.org\/10.1182\/blood.v99.10.3661 (2002).","journal-title":"Blood"},{"issue":"1","key":"1600_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00262-009-0724-5","volume":"59","author":"MJ Szczepanski","year":"2010","unstructured":"Szczepanski, M. J. et al. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating Nk cell receptors. Cancer Immunol. Immunother. 59 (1), 73\u201379. https:\/\/doi.org\/10.1007\/s00262-009-0724-5 (2010).","journal-title":"Cancer Immunol. Immunother"},{"issue":"2","key":"1600_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12308-023-00536-9","volume":"16","author":"SH Park","year":"2023","unstructured":"Park, S. H. et al. Effect of changes in lymphocyte subsets at diagnosis in acute myeloid leukemia on prognosis: association with complete remission rates and relapse free survivals. J. Hematop. 16 (2), 73\u201384. https:\/\/doi.org\/10.1007\/s12308-023-00536-9 (2023).","journal-title":"J. Hematop"},{"issue":"3","key":"1600_CR38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5045\/br.2018.53.3.198","volume":"53","author":"Y Park","year":"2018","unstructured":"Park, Y. et al. The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia. Blood Res. 53 (3), 198\u2013204. https:\/\/doi.org\/10.5045\/br.2018.53.3.198 (2018).","journal-title":"Blood Res."},{"key":"1600_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.02.008","volume":"393","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z. et al. Yin-yang effect of tumor infiltrating B cells in breast cancer: from mechanism to immunotherapy. Cancer Lett. 393, 1\u20137. https:\/\/doi.org\/10.1016\/j.canlet.2017.02.008 (2017).","journal-title":"Cancer Lett."},{"issue":"4","key":"1600_CR40","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/eji.201444625","volume":"45","author":"H Tao","year":"2015","unstructured":"Tao, H. et al. Antitumor effector B cells directly kill tumor cells via the Fas\/fasl pathway and are regulated by il-10. Eur. J. Immunol. 45 (4), 999\u20131009. https:\/\/doi.org\/10.1002\/eji.201444625 (2015).","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"1600_CR41","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1002\/ijc.31850","volume":"144","author":"M Liu","year":"2019","unstructured":"Liu, M. et al. A new perspective: exploring future therapeutic strategies for cancer by Understanding the dual role of B lymphocytes in tumor immunity. Int. J. Cancer. 144 (12), 2909\u20132917. https:\/\/doi.org\/10.1002\/ijc.31850 (2019).","journal-title":"Int. J. Cancer"},{"issue":"6","key":"1600_CR42","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/S0002-9440(10)63581-X","volume":"163","author":"A Ruddell","year":"2003","unstructured":"Ruddell, A., Mezquita, P., Brandvold, K. A., Farr, A. & Iritani, B. M. B lymphocyte-specific c-myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am. J. Pathol. 163 (6), 2233\u20132245. https:\/\/doi.org\/10.1016\/S0002-9440(10)63581-X (2003).","journal-title":"Am. J. Pathol."},{"issue":"8","key":"1600_CR43","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1593\/neo.11756","volume":"13","author":"A Ruddell","year":"2011","unstructured":"Ruddell, A., Harrell, M. I., Furuya, M., Kirschbaum, S. B. & Iritani, B. M. B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma. Neoplasia 13 (8), 748\u2013757. https:\/\/doi.org\/10.1593\/neo.11756 (2011).","journal-title":"Neoplasia"},{"issue":"1","key":"1600_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood-2008-10-184226","volume":"114","author":"D Hose","year":"2009","unstructured":"Hose, D. et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 114 (1), 128\u2013143. https:\/\/doi.org\/10.1182\/blood-2008-10-184226 (2009).","journal-title":"Blood"},{"issue":"6","key":"1600_CR45","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ijc.25791","volume":"129","author":"Z Shenghui","year":"2011","unstructured":"Shenghui, Z. et al. Elevated frequencies of cd4(+) cd25(+) cd127lo regulatory t cells is associated to poor prognosis in patients with acute myeloid leukemia. Int. J. Cancer. 129 (6), 1373\u20131381. https:\/\/doi.org\/10.1002\/ijc.25791 (2011).","journal-title":"Int. J. Cancer"},{"issue":"3","key":"1600_CR46","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/sj.leu.2404522","volume":"21","author":"E Nadal","year":"2007","unstructured":"Nadal, E. et al. Increased frequencies of cd4(+)cd25(high) t(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 21 (3), 472\u2013479. https:\/\/doi.org\/10.1038\/sj.leu.2404522 (2007).","journal-title":"Leukemia"},{"issue":"3","key":"1600_CR47","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","volume":"108","author":"M Beyer","year":"2006","unstructured":"Beyer, M. & Schultze, J. L. Regulatory t cells in cancer. Blood 108 (3), 804\u2013811. https:\/\/doi.org\/10.1182\/blood-2006-02-002774 (2006).","journal-title":"Blood"},{"issue":"16","key":"1600_CR48","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.4161\/cc.8.16.9302","volume":"8","author":"S Ju","year":"2009","unstructured":"Ju, S. et al. Cd13\u2009+\u2009cd4\u2009+\u2009cd25hi regulatory t cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell. Cycle. 8 (16), 2578\u20132585. https:\/\/doi.org\/10.4161\/cc.8.16.9302 (2009).","journal-title":"Cell. Cycle"},{"issue":"9","key":"1600_CR49","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-06-2347","volume":"13","author":"SA Perez","year":"2007","unstructured":"Perez, S. A. et al. Cd4\u2009+\u2009cd25\u2009+\u2009regulatory t-cell frequency in her-2\/neu (her)-positive and her-negative advanced-stage breast cancer patients. Clin. Cancer Res. 13 (9), 2714\u20132721. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2347 (2007).","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"1600_CR50","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1182\/blood-2008-06-163048","volume":"112","author":"M Ahmadzadeh","year":"2008","unstructured":"Ahmadzadeh, M. et al. Foxp3 expression accurately defines the population of intratumoral regulatory t cells that selectively accumulate in metastatic melanoma lesions. Blood 112 (13), 4953\u20134960. https:\/\/doi.org\/10.1182\/blood-2008-06-163048 (2008).","journal-title":"Blood"},{"issue":"4","key":"1600_CR51","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/sj.bjc.6603580","volume":"96","author":"KM Lau","year":"2007","unstructured":"Lau, K. M. et al. Increase in Circulating foxp3\u2009+\u2009cd4\u2009+\u2009cd25(high) regulatory t cells in nasopharyngeal carcinoma patients. Br. J. Cancer. 96 (4), 617\u2013622. https:\/\/doi.org\/10.1038\/sj.bjc.6603580 (2007).","journal-title":"Br. J. Cancer"},{"issue":"11","key":"1600_CR52","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1182\/blood-2007-08-105395","volume":"111","author":"S Mittal","year":"2008","unstructured":"Mittal, S. et al. Local and systemic induction of cd4\u2009+\u2009cd25\u2009+\u2009regulatory t-cell population by non-hodgkin lymphoma. Blood 111 (11), 5359\u20135370. https:\/\/doi.org\/10.1182\/blood-2007-08-105395 (2008).","journal-title":"Blood"},{"issue":"5","key":"1600_CR53","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1080\/10428190902803677","volume":"50","author":"M Jak","year":"2009","unstructured":"Jak, M. et al. Enhanced formation and survival of cd4\u2009+\u2009cd25hi foxp3\u2009+\u2009t-cells in chronic lymphocytic leukemia. Leuk. Lymphoma. 50 (5), 788\u2013801. https:\/\/doi.org\/10.1080\/10428190902803677 (2009).","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"1600_CR54","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","volume":"107","author":"M Beyer","year":"2006","unstructured":"Beyer, M. et al. In vivo peripheral expansion of Naive cd4\u2009+\u2009cd25high foxp3\u2009+\u2009regulatory t cells in patients with multiple myeloma. Blood 107 (10), 3940\u20133949. https:\/\/doi.org\/10.1182\/blood-2005-09-3671 (2006).","journal-title":"Blood"},{"key":"1600_CR55","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fonc.2018.00213","volume":"8","author":"AJ Lamble","year":"2018","unstructured":"Lamble, A. J. & Lind, E. F. Targeting the immune microenvironment in acute myeloid leukemia: a focus on t cell immunity. Front. Oncol. 8, 213. https:\/\/doi.org\/10.3389\/fonc.2018.00213 (2018).","journal-title":"Front. Oncol."},{"key":"1600_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.critrevonc.2016.04.020","volume":"103","author":"R Austin","year":"2016","unstructured":"Austin, R., Smyth, M. J. & Lane, S. W. Harnessing the immune system in acute myeloid leukaemia. Crit. Rev. Oncol. Hematol. 103, 62\u201377. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.04.020 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"1600_CR57","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1600-0609.2005.00537.x","volume":"75","author":"X Wang","year":"2005","unstructured":"Wang, X. et al. Increased population of cd4(+)cd25(high), regulatory t cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur. J. Haematol. 75 (6), 468\u2013476. https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00537.x (2005).","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"1600_CR58","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000478044","volume":"64","author":"J Darrigues","year":"2018","unstructured":"Darrigues, J., van Meerwijk, J. & Romagnoli, P. Age-dependent changes in regulatory t lymphocyte development and function: a mini-review. Gerontology 64 (1), 28\u201335. https:\/\/doi.org\/10.1159\/000478044 (2018).","journal-title":"Gerontology"},{"issue":"1","key":"1600_CR59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.leu.2404032","volume":"20","author":"D Behl","year":"2006","unstructured":"Behl, D. et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 20 (1), 29\u201334. https:\/\/doi.org\/10.1038\/sj.leu.2404032 (2006).","journal-title":"Leukemia"},{"issue":"7","key":"1600_CR60","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1200\/JCO.18.00889","volume":"37","author":"C Craddock","year":"2019","unstructured":"Craddock, C. et al. Combination Lenalidomide and Azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia. J. Clin. Oncol. 37 (7), 580\u2013588. https:\/\/doi.org\/10.1200\/JCO.18.00889 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"1600_CR61","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/leu.2012.87","volume":"26","author":"E Lion","year":"2012","unstructured":"Lion, E., Willemen, Y., Berneman, Z. N., Van Tendeloo, V. F. & Smits, E. L. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 26 (9), 2019\u20132026. https:\/\/doi.org\/10.1038\/leu.2012.87 (2012).","journal-title":"Leukemia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01600-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01600-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01600-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:56:47Z","timestamp":1747454207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01600-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01600-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board at the Second Affiliated Hospital of Anhui Medical University(No.20140013).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"17128"}}